natgillin/translations-raw huggingface dataset:
Por consiguiente, no es de esperar que se produzcan interacciones si se administra junto con sustratos de los citocromos P450 o de la GPP.
Hence, no interaction is to be expected in case of concomitant administration with substances being substrates of cytochromes P450 or P-glycoprotein.
Por consiguiente, no es necesario ajustar la dosis en pacientes jóvenes.
Hence, no dose-adjustments are necessary in younger patients.
Por favor contacte con su médico si cree que puede estar embarazada.
Please contact your doctor if you think you may be pregnant.
Por favor tome Siklos por la mañana antes de desayunar con un vaso de agua o con una cantidad de comida muy pequeña.
Please take Siklos in the morning before breakfast, with a glass of water or a very small amount of food.
Por razones de seguridad, Siklos está contraindicado en pacientes con insuficiencia hepática grave (ver secciones 4.3 y 4.4).
Due to safety considerations, Siklos is contraindicated in patients with severe hepatic impairment (see sections 4.3 and 4.4).
Por tanto, Siklos puede reducir la capacidad de los varones para engendrar.
Siklos may hence decrease the ability of men to father children.
Porcilis AR-T DF er en injektionsvæske, suspension, der indeholder et non-toksisk rekombinant derivat (se afsnittet ”Hvordan virker Porcilis AR-T DF?”) af Pasteurella multocida-toksin og inaktiverede Bordetella bronchiseptica-celler.
Porcilis AR-T DF is a suspension for injection which contains a non-toxic recombinant derivative (see ‘How does Porcilis AR-T DF work?’) of the Pasteurella multocida toxin and inactivated Bordetella bronchiseptica cells.
Porcilis AR-T DF injektionsvæske, suspension til svin
Porcilis AR-T DF suspension for injection for pigs
Porcilis ColiClos injektionsvæske, suspension Svin/pictogram
Porcilis ColiClos suspension for injection Pig pictogram
Porcilis PCV ID er desuden undersøgt i tre feltundersøgelser i svinebesætninger, hvor der var PCV2- infektion.
Porcilis PCV ID has also been investigated in three field studies involving pig farms where PCV2 infection was present.
Porcilis PCV ID injektionsvæske, emulsion, til svin
Porcilis PCV ID emulsion for injection for pigs
Porcilis PCV ID injektionsvæske, emulsion, til svin
Porcilis PCV ID emulsion for injection, for pigs
Porcilis PCV injektionsvæske, emulsion
Porcilis PCV emulsion for injection
Porcilis PCV injektionsvæske, emulsion til svin
Porcilis PCV emulsion for injection for pigs
Porcilis PCV M Hyo anvendes til at beskytte svin mod to forskellige infektioner, porcint circovirus og
Porcilis PCV M Hyo is used to protect pigs against two separate infections, porcine circovirus and
Porcilis PCV M Hyo er en veterinær vaccine, der indeholder en antigen-subunit fra porcint circovirus type 2 (PCV2) og en inaktiveret (dræbt) stamme af bakterien Mycoplasma hyopneumoniae.
Porcilis PCV M Hyo is a veterinary vaccine that contains porcine circovirus type 2 (PCV2) subunit antigen and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria.
Porcilis PCV M Hyo leveres som injektionsvæske, emulsion.
Porcilis PCV M Hyo is available as an emulsion for injection.
Porcilis PCV, injektionsvæske, emulsion til svin
Porcilis PCV emulsion for injection for pigs
Porcilis Pesti indeholder et antigen – E2 (et stof, som fremkalder en immunrespons) mod CSF.
Porcilis Pesti contains an antigen – E2 (a substance that stimulates an immune response) to CSF.
Porcilis Pesti injektionsvæske, emulsion til grise
Porcilis Pesti emulsion for injection for pigs
Porcilis Pesti injektionsvæske, emulsion til svin
Porcilis Pesti emulsion for injection for pigs
Porcilis Pesti, injektionsvæske, emulsion til svin
Porcilis Pesti emulsion for injection for pigs
Porcilis Porcoli Diluvac Forte injektionsvæske, suspension
Porcilis Porcoli Diluvac Forte suspension for injection
Porcint circovirus 2
Porcine circovirus 2
Porcint circovirus og Mycoplasma hyopneumoniae vaccine (inaktiveret)
Porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated)
Porcint circovirus type 2 (PCV2) er kendt for at give en lang række kliniske symptomer og syndromer hos grise, hvoraf nogle kan skyldes PCV2 kombineret med andre stoffer.
Porcine circovirus type 2 (PCV2) is known to cause a wide variety of clinical signs and syndromes in pigs, some of which may be caused by PCV2 in combination with other agents.
Porcint circovirus type 2 ORF2 subunit antigen: ≥ 4,5 log2 ELISA enheder (som målt i in vivo- styrketest i kyllinger)
Porcine circovirus type 2 ORF2 subunit antigen: at least 4.5 log2 ELISA units (as determined in the in vivo potency test in chickens)
Porcint circovirus type 2 ORF2 subunit-antigen  1436 AU1
Porcine circovirus type 2 ORF2 subunit antigen  1436 AU1
Porcint circovirus type 2 ORF2 subunit-antigen: ≥ 4,5 log2 ELISA-enheder
Porcine circovirus type 2 ORF2 subunit antigen:  4.5 log2 ELISA units.
Porcint circovirus type 2 ORF2 subunit-antigen; mindst 4,5 log2 ELISA-enheder*
Porcine circovirus type 2 ORF2 subunit antigen: at least 4.5 log2 ELISA units
Porcint circovirus type 2 ORF2-protein RP* 1,0–3,75
Porcine circovirus type 2 ORF2 protein RP* 1.0–3.75
Porcint circovirus type 2 ORF2-protein RP* 1,0–3,75
Porcine circovirus type 2 ORF2 protein: RP* 1.0–3.75
porfyri (en sjælden blodsygdom).
porphyria (a rare blood disorder).
Porfyri eller andre sygdomme, som forværres af lys
Porphyria or other diseases exacerbated by light.
Porfyri4
Porphyria4
Porriño Pontevedra 36400 Spanien
Dublin 15 Ireland
Portal fibrose
Portal fibrosis
portal hypertension (oesophagusvaricer)
portal hypertension (oesophageal varices)
Portal venetrombose var den almindeligste TEE i begge behandlingsgrupper (2 % hos patienter, der fik eltrombopag i forhold til < 1 % i placebogruppen).
Portal vein thrombosis was the most common TEE in both treatment groups (2% in patients treated with eltrombopag versus < 1% for placebo).
Portionen med rekombinant faktor IX er identisk med Thr148-allelformen af plasmaderiveret faktor IX.
The recombinant factor IX portion is identical to the Thr148 allelic form of plasma- derived factor IX.
Portrazza + GCb (N = 538)
Portrazza + GCb (N=538)
Portrazza 800 mg koncentrat til infusionsvæske, opløsning
Portrazza 800 mg concentrate for solution for infusion
Portrazza 800 mg koncentrat til infusionsvæske, opløsning (sterilt koncentrat) er en klar til let opaliserende og farveløs til let gul væske i et hætteglas af glas med gummiprop.
Portrazza 800 mg concentrate for solution for infusion (sterile concentrate) is a clear to slightly opalescent and colourless to slightly yellow liquid in a glass vial with a rubber stopper.
Portrazza 800 mg sterilt koncentrat necitumumab
Portrazza 800 mg sterile concentrate necitumumab
Portrazza er et lægemiddel til behandling af fremskreden ikke-småcellet pladecellekræft i lungerne hos voksne.
Portrazza is a medicine for treating advanced stages of a type of lung cancer known as squamous non- small cell lung cancer.
Portrazza kan forårsage blodpropper i arterierne eller i venerne.
Portrazza can cause blood clots in your arteries or your veins.
Portsmouth, NH 03801-2815 USA
Portsmouth, NH 03801-2815 United States
Portugal
Icepharma hf.
Portugal
Malta
Portugal
Κύπρος
Portugal Portugal
Portugal
Posaconazol
with rifampicin as
Posaconazol 0,9 mg/ml
Posaconazole 0.9 mg/mL
Posaconazol er 40-100 gange mere potent in vitro mod Malassezia pachydermatis sammenlignet med clotrimazol, miconazol og nystatin.
Posaconazole is 40 – 100 times more potent in vitro against Malassezia pachydermatis than clotrimazole, miconazole and nystatin.
Posaconazol havde ingen indvirkning på hanrotters fertilitet ved doser på op til 180 mg/kg (3,4 gange 300 mg tabletten baseret på plasmakoncentrationer ved steady-state hos patienter) eller hunrotter ved en dosis på op til 45 mg/kg (2,6 gange 300 mg tabletten baseret på plasmakoncentrationer ved steady- state hos patienter).
Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (3.4 times the 300-mg tablet based on steady-state plasma concentrations in patients) or female rats at a dose up to 45 mg/kg (2.6 times the 300-mg tablet based on steady-state plasma concentrations in patients).
Posaconazol kan øge plasmakoncentrationen af vinkaalkaloider (f.eks. vincristin og vinblastin), hvilket kan føre til neurotoksicitet.
Posaconazole may increase the plasma concentration of vinca alkaloids (e.g. vincristine and vinblastine), which may lead to neurotoxicity.
Posaconazol metaboliseres via UDP glucuronidering (fase 2 enzymer) og er et substrat for p- glycoprotein (P-gp) efflux in vitro.
Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for p- glycoprotein (P-gp) efflux in vitro.
Posaconazol metaboliseres via UDP-glukuronidering (fase 2 enzymer) og er et substrat for p- glykoprotein (P-gp) efflux in vitro.
Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for p- glycoprotein (P-gp) efflux in vitro.
posaconazol og efavirenz
posaconazole and efavirenz
posaconazol og efavirenz bør
alternative antifungal treatment should be considered.
posaconazol og efavirenz bør
posaconazole and efavirenz
Posaconazol oral suspension (200 mg eller 400 mg) forlængede ydermere middelterminalhalveringstiden af midazolam fra omkring 3-4 timer til 8-10 timer under samtidig administration.
In addition, posaconazole oral suspension (200 mg or 400 mg) prolonged the mean terminal half-life of midazolam from approximately 3-4 hours to 8- 10 hours during co-administration.
Posaconazol tablet
Posaconazole tablet
posaconazol voriconazol
posaconazole
posaconazol voriconazol
posaconazole voriconazole
posaconazol.
and posaconazole.
Posaconazol/ tenofovirdisoproxilfumarat
Posaconazole/Tenofovir disoproxil fumarate
Posaconazol/efavirenz
Itraconazole/Efavirenz
Posaconazol/efavirenz
Posaconazole/Efavirenz
Posaconazol3 Fluconazol
Fluconazole
Posaconazol:
Itraconazole:
Posaconazol: AUC: ↓ 50%
Posaconazole: AUC: ↓ 50
Posaconazole SP 40 mg/ml oral suspension posaconazol
Posaconazole SP 40 mg/ml oral suspension posaconazole
Posaconazole SP anvendes desuden til behandling af patienter med "trøske" (oropharyngeal candidiasis), som er en svampeinfektion i munden og svælget forårsaget af Candida.
Posaconazole SP is also used to treat patients with oropharyngeal candidiasis or ‘thrush’, a fungal infection of the mouth and throat due to Candida.
Posaconazole SP bør altid tages i nøje overensstemmelse med Deres læges instruktioner.
Posaconazole SP must only be used as directed by your doctor.
Posaconazole SP indeholder cirka 1,75 g glucose per 5 ml suspension.
Posaconazole SP contains approximately 1.75 g of glucose per 5 ml of suspension.
Posaconazole SP kan anvendes til behandling af følgende svampeinfektioner hos voksne:
Posaconazole SP can be used to treat the following types of fungal infections in adults:
Posaconazolplasmakoncentrationer (Cmax og AUC) reduceredes med 39 %, da posaconazol blev administreret samtidig med cimetidin (400 mg 2 gange dagligt) på grund af reduceret absorption, som muligvis var sekundær til reduktion af mavesyreproduktionen.
Posaconazole plasma concentrations (Cmax and AUC) were reduced by 39 % when posaconazole was administered with cimetidine (400 mg twice a day) due to reduced absorption possibly secondary to a decrease in gastric acid production.
Posaconazols farmakokinetik er sammenlignelig hos mænd og kvinder.
The pharmacokinetics of posaconazole are comparable in men and women.
Posatex øredråber
Posatex
Posatex øredråber til hunde
Posatex ear drops for dogs
Posatex øredråber til hunde
Posatex ear drops suspension for dogs
Posatex øredråber, suspension til hunde
Posatex ear drops suspension dogs
Posatex øredråber, suspension til hunde.
Posatex ear drops suspension for dogs
Posatex øredråber, suspension til hunde.
Posatex, ear drops suspension for dogs
Pose
Bag
POSE
POUCH
Pose
Sachet
pose (EVA)
bag (EVA)
Pose (plastik)
Bag (plastic)
Pose (Polyester/Alu)
sachet (polyester/alu)
pose (PP/PP)
bag (PP/PP)
POSE (uden blue box)
BAG (without blue box)
Pose af aluminiumsfolie indeholdende 1, 3 eller 5 intraruminal(t)(e) indlæg.
Aluminium foil bag containing 1, 3 or 5 intraruminal device(s).
POSE ETIKET
BAG LABEL
Pose indeholdende fyldt injektionssprøjte, en stempelstopper og isat stempel
POUCH containing pre-filled syringe, a plunger stopper and a pre-attached plunger rod
POSE INDEHOLDENDE STRIP MED 5 ENKELTDOSISBEHOLDERE
POUCH CONTAINING STRIP OF 5 SINGLE-DOSE CONTAINERS
POSE MED SOLVENS
SOLVENT BAG
Posen indeholder et volumen af 10-100 ml frossen dispersion med en koncentration af 5-20 x 106 celler/ml.
The bag contains a volume of 10-100 mL of frozen dispersion at a concentration of 5-20 x 106 cells/mL
Posen kræver ikke særlige opbevaringsbetingelser.
The bag does not require any specific storage conditions.
Posen med tørremiddel skal kasseres, og indholdet må ikke spises eller inhaleres.
The desiccant sachet should be thrown away and it should not be eaten or inhaled.
Posen må ikke omrystes.
Do not shake the bag.
Posen og tørremidlet kasseres.
The pouch and desiccant should be discarded.
Posen skal fjernes fra det flydende kvælstof, anbringes i en dobbelt posebeholder og optøs i et vandbad, der på forhånd er opvarmet til 37 °C. Når celledispersionen er helt optøet, tørres og desinficeres posen, hvorefter dispersionen er klar til at blive infunderet ved den af lægen ordinerede hastighed.
The bag should be removed from the liquid nitrogen, put in a double bag container and thawed in a pre-warmed water bath at 37 °C. Upon full cell dispersion thawing, the bag is dried, disinfected and ready to be infused at a rate prescribed by the physician.
Posen skal forsigtig vendes op og ned for at blande opløsningen.
The bag should be gently inverted in order to mix the solution.
Posen skal undersøges visuelt for partikler.
The bag must be visually inspected for particulate matter.
Posenr.:
Bag No.:
Poser (papir/PE/alu/P E)
Sachet (paper/PE/A lu/PE)
Poser med solvens
Bags of diluent
Poser og medicinsk udstyr af PVC må derfor ikke anvendes til forberedelse, opbevaring og indgift af Torisel opløsning til infusion.
Therefore, PVC bags and medical devices must not be used for the preparation, storage and administration of Torisel solutions for infusions.
Poser/beholdere, der kommer i kontakt med Torisel, skal være fremstillet af glas, polyolefin, eller polyethylen.
Bags/containers that come in contact with Torisel must be made of glass, polyolefin, or polyethylene.
Poserne med tørremiddel må ikke spises eller åbnes.
Do not eat or open the desiccant sachets.
Posibles efectos adversos
Possible side effects
Positionel vertigo, sygdom i det indre øre, ubehag i øret
Ear discomfort, inner ear disorder, vertigo positional
Positionen af disse mutationer er ikke konsistente mellem forskellige isolater.
The position of these mutations was not consistent between different isolates.
positionsvertigo, vertigo
Vertigo positional, vertigo
Positiv
Coombs
positiv
mutation- positive
positiv
mutation-positive
positiv < baseline
(2/25)
positiv < baseline
(23/25)
Positiv anti-thyroid-antistof
Anti-thyroid antibody positive
Positiv bestemmelse af T790M-mutationsstatus, hvor der enten er anvendt en vævsbaseret eller en plasmabaseret test, indikerer egnethed for behandling med Tagrisso.
Positive determination of T790M mutation status using either a tissue-based or plasma-based test indicates eligibility for treatment with TAGRISSO.
Positiv blodprøve for lupus
Positive blood lupus test
Positiv Coombs test*
Coombs test positive
Positiv Coombs test, fald i systolisk blodtryk, stigning i systolisk blodtryk, stigning i legemstemperatur
Coombs test positive, blood pressure systolic decreased, blood pressure systolic increased, body temperature increased
Positiv Coombs test, forhøjet gamma-glutamyl-transpeptidase (GGT) i serum, forhøjet alkalisk fosfatase i serum
Coombs test positive, increased serum gamma-glutamyl transpeptidase (GGT), increased serum alkaline phosphatase
Positiv direkte Coombs’ test
Direct Coombs’ test positive
Positiv sandsynligheds- ratio
Positive likelihood ratio
Positiv test for antityroide antistoffer
Anti-thyroid antibody positive
Positiv test for hiv (humant immundefektvirus) eller et andet agens, som er anført i EU's gældende celle- og vævsdirektiv.
Positive test for human immunodeficiency virus (HIV) or any other agent listed in the current EU Cell and Tissue Directive.
Positiv test for røde blodceller i urinen, fald i natrium i blodet, vægttab, fald i neutrofiltal, glucose i urinen, øget diurese
red blood cells urine positive, blood sodium decreased, weight decreased, neutrophil count decreased, glucose urine present, urine output increased
Positiv test for røde blodceller i urinen, hyponatriæmi, vægttab, fald i neutrofiltal, glukosuri, øget urinudskillelse
red blood cells urine positive, blood sodium decreased, weight decreased, neutrophil count decreased, glucose urine present, urine output increased
Positiv test for røde blodlegemer i urinen, hyponatriæmi , vægttab, fald i neutrofiltal, glucose i urinen, øget urinmængde
red blood cells urine positive, blood sodium decreased, weight decreased, neutrophil count decreased, glucose urine present, urine output increased
Positiv test for røde blodlegemer i urinen, hyponatriæmi, vægttab, fald i neutrofiltal, glucose i urinen, øget urinmængde
red blood cells urine positive, blood sodium decreased, weight decreased, neutrophil count decreased, glucose urine present, urine output increased
Positiv urinprotein (> 1+)x
Dysmenorrhoea
Positiv urinprotein (>1+)x
Urinary protein positive (>1+)
positive
0.74
positive blodprøveresultater for anti-neutrofilocyt cytoplasma-antistof og glat muskel-antistof
blood test results positive for antineutrophil cytoplasmic antibody and smooth muscle antibody
positive blodprøveresultater for antinukleære antistoffer
blood test results positive for antinuclear antibody
Positive scanninger har enten:
Positive scans will have either:
Positivitet for anti- neutrofilocyt cytoplasma- antistof og glat muskel- antistof
Antineutrophil cytoplasmic antibody positive, smooth muscle antibody positive
Positivt resultat defineres i dette afsnit som fuldstændigt eller delvis respons.
Successful outcome in this section is defined as complete or partial response.
Posologi:
Posology
Posología
Posology
Posología y forma de administración
Posology and method of administration
Possia (%/år) N=9235
Possia (%/year) N=9235
Possia 90 mg filmovertrukne tabletter
Possia 90 mg film coated tablets
Possia 90 mg tabletter ticagrelor
Possia 90 mg tablets ticagrelor
Possia anbefales ikke til børn og teenagere under 18 år.
Possia is not recommended for children and adolescents under 18 years.
Possia bør ikke anvendes under graviditeten.
Possia is not recommended during pregnancy.
Possia fås i:
Possia is available in:
Possia og clopidogrel adskilte sig ikke med hensyn til hyppighed af PLATO Major Fatal/Life- threatening bleeding, PLATO total Major bleeding, TIMI Major bleeding eller TIMI Minor bleeding (Tabel 2).
Possia and clopidogrel did not differ in rates of PLATO Major Fatal/Life-threatening bleeding, PLATO total Major bleeding, TIMI Major bleeding, or TIMI Minor bleeding (Table 2).
Possia påvirker celler, der kaldes ”blodplader” eller ”trombocytter”.
Possia affects cells called ‘platelets’ (also called thrombocytes).
Possia påvirker ikke tests af lungefunktionen.
Possia does not affect tests of pulmonary function.
Possia reducerede forekomsten af det primære sammensatte endepunkt sammenlignet med clopidogrel i både UA/NSTEMI- og STEMI-populationen (tabel 3).
Possia reduced the occurrence of the primary composite endpoint compared to clopidogrel in both the UA/NSTEMI and STEMI population (Table 3).
Possia var imidlertid ikke mere effektivt end clopidogrel til at reducere risikoen for slagtilfælde.
However Possia was not more effective than clopidogrel in reducing the risk of stroke.
Possia vil sandsynligvis ikke påvirke din evne til at køre eller betjene værktøj eller maskiner.
Possia is not likely to affect your ability to drive or use machines.
Possia, der administreres sammen med acetylsalicylsyre (ASA), er indiceret til forebyggelse af aterotrombotiske hændelser hos voksne patienter med akut koronarsyndrom (ustabil angina, non-ST- elevationsmyokardieinfarkt [NSTEMI] eller ST-elevationsmyokardieinfarkt [STEMI]), herunder medicinsk behandlede patienter og patienter behandlet med perkutan koronar intervention (PCI) eller koronar bypassoperation (CABG).
Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
Possia-behandling skal indledes med en enkelt 180 mg mætningsdosis (to tabletter på hver 90 mg) og derefter fortsættes med 90 mg to gange dagligt.
Possia treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily.
Post dosis 1
Post- dose 1
Post dosis 2
Post- dose 2
Post hoc ikke-stratificerede subgruppeanalyser af RAINBOW-patienter, som tidligere var behandlet med trastuzumab (n=39), tyder på en overlevelsesfordel for disse patienter (HR 0,679, 95 % Ki 0,327; 1,419), og viste en fordel mht. progressionsfri overlevelse (PFS) (HR 0,399, 95
Post hoc unstratified subgroup analyses from RAINBOW patients previously treated with trastuzumab (n= 39) suggested a survival benefit in such patients (HR 0.679, 95% CI 0.327, 1.419) and demonstrated a benefit for progression free survival (PFS) (HR 0.399, 95% CI 0.194, 0.822).
Post hoc-analyser har identificeret højt-responderende subgrupper, f.eks. patienterne med et lavt komplementniveau og positiv anti-dsDNA ved baseline (se tabel 2).
Post-hoc analysis has identified high responding subgroups such as those patients with low complement and positive anti-dsDNA at baseline, see Table 2.
Post marketing er der rapporteret om tilfælde af leukæmi hos patienter, som blev behandlet med en TNF-antagonist.
In the post marketing setting, cases of leukemia have been reported in patients treated with a TNF-antagonist.
Post marketing overvågning:
Post marketing surveillance:
Post marketing-studier, der viser effektivitet ved forebyggelse af RV-gastroenteritis (RVGE)
Post marketing studies demonstrating effectiveness to prevent RV gastroenteritis (RVGE)
Post partum (6-12 uger) (n=11)
Postpartum (6-12 weeks) (n=11)
Post partum (6-12 uger) (n=15)
Postpartum (6-12 weeks) (n=11)
Post partum (6-12 uger) (n=15)
Postpartum (6-12 weeks) (n=15)
Post- dosis 1
Post- Dose 1
Post- dosis 2
Post- Dose 2
Post-bronkodilatator- FEV1 steg i roflumilast-gruppen med 52 ml (95% CI: 40-65 ml) og faldt i placebo-gruppen med 4 ml (95% CI: -16; 9 ml).
Post-bronchodilator FEV1 increased for the roflumilast group by 52 mL (95% CI: 40, 65 mL) and decreased for the placebo group by 4 mL (95% CI: -16, 9 mL).
Post-eksponerings-profylakse: Alvorlig hepatotoksicitet, inkl. leversvigt der krævede transplantation, er blevet rapporteret hos ikke-hiv-smittede personer, som fik multiple doser af Viramune i forbindelse med post-eksponerings-profylakse (PEP), som er en ikke godkendt anvendelse.
Post-Exposure-Prophylaxis: Serious hepatotoxicity, including liver failure requiring transplantation, has been reported in HIV-uninfected individuals receiving multiple doses of Viramune in the setting of post-exposure-prophylaxis (PEP), an unapproved use.
Post-eksponerings-profylakse: Alvorlig hepatotoksicitet, inkl. leversvigt påkrævende transplantation, er blevet rapporteret hos ikke hiv-smittede personer, som fik multiple doser af Viramune i forbindelse med post-eksponerings-profylakse (PEP), en ikke godkendt anvendelse.
Post-Exposure-Prophylaxis: Serious hepatotoxicity, including liver failure requiring transplantation, has been reported in HIV-uninfected individuals receiving multiple doses of Viramune in the setting of post-exposure-prophylaxis (PEP), an unapproved use.